

# Options Limited for Psoriasis During Pregnancy

BY DIANA MAHONEY

BOSTON — Data suggesting that pregnant women with psoriasis have poorer outcomes than those without it highlight the need for more research to determine whether the outcome discrepancies are a function of the disease itself, comorbidities, or treatment side effects, according to Dr. Alexa Boer Kimball.

"We know that pregnancy can have an impact on psoriasis—studies have shown that about 50% of women report improvements; 15%-25% worsen; and the rest don't change—but we know less about the effect of psoriasis on pregnancy," said Dr. Kimball of the department of dermatology at Harvard Medical School in Boston.

In a case-control study of 145 live births in women with psoriasis between 1998 and 2004, investigators at Ben Gurion University of the Negev in Beer-Sheva, Israel, demonstrated an association between pregnancy complications and psoriasis. Specifically, recurrent abortions and chronic hypertension were significantly associated with psoriasis in a multivariate analysis, and psoriasis was an independent risk factor for cesarean delivery (*J. Reprod. Med.* 2008;53:183-7).

"The findings are not really surprising when you think about the [inflammatory bowel disease] literature and the lupus literature, for example. It's clear that systemic autoimmune diseases can have adverse effects on pregnancies," Dr. Kimball said at the American Academy of Dermatology's Academy 2009 meeting.

"Unfortunately, our knowledge about pregnancy outcomes in psoriasis is very limited, which in turn limits the treatment guidance that we can offer." This is due, she said, to the dearth of literature on the topic, the exclusion of pregnant women from most clinical trials, and the low enrollment in pregnancy registries.

Further, said Dr. Kimball, the various regulatory agencies are not consistent in interpreting numerical data regarding drug safety in pregnancy. In one study comparing the pregnancy risk classification of 236 commonly used drugs by three international regulatory agencies—

the U.S. Food and Drug Administration, the Australian Drug Evaluation Committee, and the Swedish Catalogue of Approved Drugs—only 26% of the drugs were placed into the same risk category, she said (*Drug Saf.* 2000;23:245-53).

"Theoretically, these groups should be looking at the same data and arriving at essentially the same conclusions. The fact that they're not tells you that there is a substantial subjective review component to how we evaluate this information," she said.

For these reasons, providing therapeutic guidance to pregnant women with psoriasis is "incredibly challenging," Dr. Kimball said.

The challenge is exacerbated by several social and environmental considerations, including the fact that "women today are under extraordinary pressure not to expose their babies to unknown and unnecessary risks, which may make them more likely to forego therapy that they might actually need," she said. "In counseling these patients, there really obviously has to be a very open communication about that, although you really can't make the choice for them. It's a very personal decision about the risks they're willing to take."

Similarly, there is tremendous pressure on women to breastfeed for long periods of time, which can also have an impact on treatment decisions. "A woman may decide to hold off on treatment while she's breastfeeding, and again that's a personal decision, but recognize that it may be a really substantial sacrifice, and in cases of psoriatic arthritis in particular, it may not be all that good for them over time," she said.

In addition to helping patients determine how to proceed with treatment once they are pregnant, patient counseling should address exposures that might have already happened. "The critical period in all pregnancies for fetal malformations is early, in the first trimester, and

lots of women are exposed to drugs before they even know they're pregnant," said Dr. Kimball.

"In situations involving major risks, referral to a genetics counselor can be useful, but it's also important to remind patients that, under the best of circumstances, not all pregnancies turn out perfectly. The developmental disorder rate [in the general population] is about 3% at birth and about 8% by age 5. It's important to give that information

**Women are under extraordinary pressure not to expose their babies to unnecessary risks, which may make them more likely to forego therapy that they might actually need.**

to women so they don't feel overly guilty about the choices they're making," she said.

"So what can we actually recommend?" Dr. Kimball asked.

"For first-line therapy, moisturizers can be used with reckless abandon, and low-potency topical steroids have been determined to not be a risk." Systemic steroids, on the other hand, should be avoided in the first trimester because of the association with cleft palate, she said.

The second-line treatment algorithm includes narrow band ultraviolet B (UVB) phototherapy, if feasible, "but this may be a challenge if, for example, the pregnant woman has other kids at home or just doesn't have the flexibility in terms of scheduling," Dr. Kimball said. "Home UVB is an option, and tanning beds—although problematic for other reasons—in a severe patient might be worth considering if they really have no other options."

Concern regarding the possibility that folate levels might be affected by light therapy, Dr. Kimball noted, has been put to rest by a new study showing that UVB phototherapy does not influence serum and red cell folate levels in psoriasis (*J. Am. Acad. Dermatol.* 2009;61:259-62).

The question of heat exposure has not been addressed, however. "There are recommendations against hot tubs and hot baths in the first trimester, for example, because of potential injury to the fetus, so if you have someone way up on

the light scale, that might be something worth thinking about."

Tumor necrosis factor inhibitors fall under third-line therapies. "Obviously we have limited data on these. They are generally risk category B, so most people feel reasonably comfortable if we had to go that direction, but there are potential risks that are unclear," Dr. Kimball said.

Cyclosporine, which was the therapy of choice prior to the biologics era, is another third-line treatment, said Dr. Kimball. "Although cyclosporine is [risk] category C, we probably have the best information about this drug due to the transplant registries that are out there," she noted.

It is associated with a low birth rate and prematurity, "so there are known risks associated with it, but malformations do not seem to be an issue." Systemic steroids in the second and third trimester would be another third-line option if needed, she said.

Among the systemic therapies to avoid in pregnancy are PUVA, which can potentially lead to premature labor or fetal abnormalities; methotrexate, which is a teratogen and immunogen; and systemic retinoids, which are also known teratogens, Dr. Kimball said. With respect to methotrexate in pregnancy, "the current recommendation extends to males, who should be advised to cease its use for 3 months prior to conception because of theoretical concern about chromosomal abnormalities," she noted.

Regarding topical therapies, tazarotene, anthralin, calcipotriol, and coal tar should be avoided as well, said Dr. Kimball.

In all cases, putting a patient's risk into context is difficult given the limited and conflicting information that is available, Dr. Kimball said. "At the end of the day, you really have to guide women about the personal nature of these choices," based on experience and the information that is available.

Dr. Kimball has served as a consultant and an investigator for Amgen Inc., Centocor Inc., Abbott Laboratories, NeoStrata Co., and Galderma; she is an investigator for Stiefel Laboratories Inc.; and has a fellowship funded by Centocor. ■

## Most Melanomas Are Discovered During Full-Body Exam

BY MARY ANN MOON

In patients attending a general dermatology practice, most melanomas diagnosed during a 3-year period were not the presenting complaint, but were only discovered because a dermatologist performed a full-body skin examination.

Such melanomas, discovered incidentally during an unrelated office visit, were more likely to be thinner or in-situ lesions than those that were inquired about by the patient or someone who observed them on the patient, said Dr. Jonathan Kantor and Deborah E. Kantor, CRNP, of North Florida Dermatology Associates, Jacksonville.

The U.S. Preventive Service Task Force has stated that current evidence is insufficient to recommend either for or against routine full-body melanoma screening, and

previous studies of patients in tertiary referral centers have reported that physicians detect only 14%-34% of melanomas.

"Our aim was to determine the proportion of patients in a private dermatology practice in whom melanoma was detected but was not the presenting complaint. If a substantial proportion of melanomas are detected only after a dermatologist's examination, this may suggest that FBSE (full-body skin examination), and not simply a problem-focused approach, should at least be considered for selected patients," the researchers said.

The investigators performed a retrospective case series of all patients diagnosed as having melanoma (51 cases) or melanoma in situ (75 cases) during a 3-year period. Patients were aged 15-92 years (mean age, 60 years).

A total of 56% of the melanomas were discovered by

a dermatologist and had not been noted by the patient, a spouse, a friend, or another physician. Similarly, 60% of the melanomas-in-situ were discovered by a dermatologist, they said (*Arch. Dermatol.* 2009;145:873-6).

"Moreover, we found that dermatologist detection was associated with thinner melanomas and an increasing likelihood of the melanoma being in-situ," they said.

"Thus, full-body skin examinations confer both an absolute benefit (detecting most melanomas) as well as a clinically significant marginal benefit (detecting melanomas with less tumor thickness). We hope that these findings will help spur large population-based studies in high-risk populations to develop an evidence-based approach to determining appropriate screening practices and intervals," the investigators added.

The researchers reported no financial disclosures. ■